The Vpx lentiviral vector is effective at transducing human monocytes, macrophages, and dendritic cells. The vector will broaden the utility of Carisma's engineered monocyte and macrophage platforms by enabling integration of transgenes for long-term, durable expression.

Carisma is partnering on the project with Nathaniel Landau, PhD, a professor in the department of microbiology at the NYU Grossman School of Medicine and inventor of the Vpx lentiviral vector.

The partnership builds on Carisma's recent U.S. Food and Drug Administration clearance of an investigational new drug (IND) application for its lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). The company plans to begin a phase I clinical trial for the candidate in solid tumors later this year.

Expression Therapeutics develops stem cell lentiviral gene therapy
Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3.

Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration....

Horizon Discovery accelerates CRISPR gene editing workflows
Horizon Discovery Group has introduced a new stably expressing Cas9 cell line for knockout experiments and a dCas9-VPR cell line for gene activation experiments.

Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting...